Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Faron logo — A CLEVER Approach to Fight Cancer.

Faron

A CLEVER Approach to Fight Cancer.

Founded 2007 Finland Finland 60 employees Post-IPO Debt Total: $61.34M Biopharma, Biotechnology +1

General Information

Company Name Faron
Founded Year 2007
Location Finland Finland
Founders / Decision Makers
Team member
Employees 60
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Post-IPO Debt
Business Model B2B, B2B2B
Revenue Model Licensing, Performance Based
Offices as of Nov 2026
Turku, Finland
Social

BounceWatch is an independent company data service, not affiliated with Faron. To contact Faron, visit faron.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Faron compare?

A PDF of Faron and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Faron soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Faron

Faron, a clinical stage biopharmaceutical company with the slogan "A CLEVER Approach to Fight Cancer," is focused on developing novel immunotherapies to address unmet medical needs. Headquartered in Turku, Finland, and Boston, Massachusetts, its flagship program is bexmarilimab, an investigational precision immunotherapy. Currently in Phase I/II development, bexmarilimab is a notable anti-Clever-1 antibody designed to convert immune suppression into immune activation, specifically targeting hematological malignancies.

Founded in 2007, Faron operates within the Biopharma, Biotechnology, and Pharmaceutical industries. The company is publicly traded on AIM under the ticker 'FARN' as well as on Nasdaq First North Growth Market under the ticker FARON. Its most recent financial activity includes a €3.20M Post-IPO Debt investment in March 2024 from IPF Partners, indicating continuous investor confidence in its innovative therapeutic approaches.

Business keywords: clinical stage biopharmaceutical, bexmarilimab, precision immunotherapy, macrophage checkpoint immunotherapy, hematological malignancies, anti-Clever-1 antibody, immune activation, acute organ traumas, vascular damage, drug discovery, drug development, cancer immunotherapy, ARDS, acute respiratory distress syndrome, novel treatments for unmet medical needs

Services & Products

Development of innovative cancer therapies
Conducting clinical trials
Research in immunotherapy and myeloid cell-targeting
Drug candidate investigation and development

Target Customers

Cancer patients Healthcare professionals Clinical researchers Investors in biopharmaceuticals

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt €3.20M 1
IPF Partners
IPF Partners
04 Mar 2024
Post IPO Equity €12.00M 1
The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society
27 Jan 2023
Post IPO Equity €5.00M 1
The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society
28 Jun 2022
Post IPO Debt $30.00M 1
IPF Partners
IPF Partners
28 Feb 2022
Post IPO Debt €2.10M 1
Business Finland
Business Finland
15 Jun 2020
Grant €2.50M 1
European Innovation Council
European Innovation Council
11 Jun 2020
Post IPO Equity Undisclosed 1
European Innovation Council
European Innovation Council
20 Mar 2020
Post IPO Equity £5.00M -
03 Mar 2017
Grant €1.54M 1
Business Finland
Business Finland
21 Dec 2015

Faron Alternatives & Competitors

View All Alternatives
Faron vs
CytoAgents, Inc
CytoAgents, Inc United States

Calming the Cytokine Storm, Rebalancing the Immune System. Accessible treatment for multiple areas...

Series A
10 employees
Biotechnology, Health Care
Compare Faron vs CytoAgents, Inc
Faron vs
MACROPHAGE PHARMA LIMITED
MACROPHAGE PHARMA LIMITED

Empowering the immune system to combat cancer with precision-targeted therapies

Series A
Biotechnology, Pharmaceutical
Compare Faron vs MACROPHAGE PHARMA LIMITED
Faron vs
Chordia Therapeutics Inc
Chordia Therapeutics Inc Japan

We are passionate to deliver first in class cancer drugs to patients from Japan.

IPO
12 employees
Biotechnology, Health Care
View all alternatives

FAQ About Faron

A CLEVER Approach to Fight Cancer.
Faron was founded in 2007.
Faron is headquartered in Finland. As of Nov 2026, it also has offices in Turku, Finland.
Faron operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on clinical stage biopharmaceutical, bexmarilimab, precision immunotherapy and macrophage checkpoint immunotherapy. Its customers include Cancer patients, Healthcare professionals and Clinical researchers.
Faron has a B2B and B2B2B business model. Its revenue comes from Licensing and Performance Based.
Faron has approximately 60 employees.
Faron has completed 9 funding rounds, raising a total of $61.34M. The latest funding stage is Post-IPO Debt.
Faron offers: Development of innovative cancer therapies, Conducting clinical trials, Research in immunotherapy and myeloid cell-targeting, Drug candidate investigation and development.
Top alternatives and competitors to Faron include CytoAgents, Inc, MACROPHAGE PHARMA LIMITED, Chordia Therapeutics Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Faron and CytoAgents, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Faron, https://bouncewatch.com/company/faron, updated 5 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout